-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The development of the new coronavirus-19 vaccine has been unprecedented.
The frequency of VITT varies by age group
Reported the experience of four VITT patients from a tertiary referral center in London, England, who suffered from cerebral venous sinus thrombosis (CVST) with or without thrombosis elsewhere
This article was published in the " Journal of Neurology, Neurosurgery & Psychiatry " ( Journal of Neurology, Neurosurgery & Psychiatry )
All four patients were 41-46-year-old women who were diagnosed with VITT 7-28 days after ChAdOx1 nCov-19 vaccination
All four patients were 41-46-year-old women who were diagnosed with VITT 7-28 days after ChAdOx1 nCov-19 vaccination
Cranial effects of four patients with immune thrombotic thrombocytopenia induced by cerebral venous sinus thrombosis vaccine
Three-quarters and two-quarters of patients had thrombocytopenia and hypofibrinogenemia, respectively, and D-dimer was significantly elevated in all four patients
Three-quarters and two-quarters of patients had thrombocytopenia and hypofibrinogenemia, respectively, and D-dimer was significantly elevated in all four patients
CT image at the level of the main pulmonary artery
Adopt a unified treatment method, emergency plasma exchange (PLEX) combined with intravenous immunoglobulin (IVIg) and high-dose steroids (1 g methylprednisolone intravenously, then 20 mg dexamethasone intravenously or orally, Continue for 4 days, and gradually reduce the dose over the next few days) and a non-heparin anticoagulant containing rituximab (initially argatroban) (375 mg/m2)
Adopt a unified treatment method, emergency plasma exchange (PLEX) combined with intravenous immunoglobulin (IVIg) and high-dose steroids (1 g methylprednisolone intravenously, then 20 mg dexamethasone intravenously or orally, Continue for 4 days, and gradually reduce the dose over the next few days) and a non-heparin anticoagulant containing rituximab (initially argatroban) (375 mg/m2)
The treatment of the four patients described in this article represents a positive VITT treatment, which plays a central role in the good prognosis of the patient
This is the first study combining VITT imaging to study immunity, coagulation/hemostasis, platelet and endothelial dysfunction
Leave a message here
